Comparative Pharmacology
Head-to-head clinical analysis: K 10 versus K LEASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K 10 versus K LEASE.
K+10 vs K-LEASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium ion replacement; essential for maintenance of intracellular tonicity, nerve impulse transmission, cardiac and skeletal muscle contraction, and acid-base balance.
Potassium ion replacement therapy; increases extracellular potassium levels to correct hypokalemia.
IV: 10 mEq potassium chloride infused at a rate not exceeding 10 mEq/hour via peripheral line; maximum 20 mEq/hour via central line with continuous ECG monitoring. Oral: 20-40 mEq per day in divided doses; maximum 100 mEq per day.
1 tablet (25 mEq) orally 2-4 times daily with meals; maximum 100 mEq/day.
None Documented
None Documented
Potassium does not have a true elimination half-life as it is an endogenous ion under homeostatic control. However, intravenously administered potassium has a distribution half-life of approximately 1-1.5 hours and a slow terminal phase reflecting cellular redistribution and eventual excretion. Clinical context: The apparent half-life is highly dependent on renal function and body stores.
Not applicable; exogenous potassium is not subject to terminal elimination half-life as it is rapidly redistributed and excreted. Clinical context: the half-life of redistribution is minutes to hours.
Potassium is primarily excreted via the kidneys (approximately 90%) with the remainder lost in feces (via colonic secretion). In patients with normal renal function, urinary potassium excretion accounts for >90% of elimination. Fecal excretion is minimal (≤10%) but increases in renal impairment.
Excreted renally as potassium chloride; elimination is 100% renal. No biliary or fecal excretion.
Category C
Category C
Potassium Supplement
Potassium Supplement